Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
NG Bio is an early-stage investor and venture builder based in London, UK, founded to address harmful immune responses, particularly inflammation, which contribute to major human diseases. The organization is dedicated to extending human health span and longevity through innovative therapeutic solutions. Since its inception, NG Bio has focused on the life sciences sector, specifically targeting therapeutic development related to autoimmune diseases.
Currently, NG Bio manages a portfolio of six companies and operates with a team of experienced professionals. The firm engages in venture creation, providing support to its portfolio companies in financing strategies, growth, and exit planning. Their commitment to the life sciences sector positions them as a significant player in the UK biotech landscape.
NG Bio invests primarily in the life sciences sector, with a specific emphasis on therapeutic development related to autoimmune diseases and inflammation. The firm participates in various investment stages, including pre-seed, seed, seed-plus, and Series A. Their investment strategy is centered around supporting companies that are innovating in the field of therapeutics, particularly those addressing harmful immune responses.
NG Bio seeks to partner with founders who are developing solutions that can significantly impact human health. They provide comprehensive support throughout the investment lifecycle, including assistance with financing strategies, growth initiatives, and exit planning. This hands-on approach enables portfolio companies to navigate the complexities of the biotech industry effectively.
NG Bio's portfolio includes six notable companies that are making strides in the life sciences sector:
Among these, Cellesce stands out as a notable exit, having been acquired by Molecular Devices, showcasing NG Bio's capability in identifying and nurturing high-potential companies.
Mohammad Khobreh, MSc - Managing Partner, Co-founder. He has extensive experience in venture capital and life sciences, focusing on therapeutic development.
Jason Goldstein, MBA CA - General Partner, Co-founder. Jason brings a strong background in finance and investment strategy, with a focus on early-stage biotech companies.
Richard Kaschula, PhD - Principal. Richard has a deep understanding of the life sciences sector and has been involved in various successful biotech ventures.
Tim Carlton, PhD - Director, Drug Development. Tim specializes in drug development and has a strong track record in advancing therapeutic solutions in the biotech field.
To pitch NG Bio, founders should submit their proposals through the NG Bio website. A comprehensive pitch deck is essential, including information on the technology, market opportunity, team, and financial projections. NG Bio prefers clear and concise presentations that articulate the startup's vision and potential impact.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory.
NG Bio runs a program designed to support early-stage biotech companies. This program focuses on venture creation, providing resources and guidance to help startups navigate the complexities of the life sciences sector. Eligibility typically includes being in the pre-seed to Series A stages and having a focus on therapeutic development related to autoimmune diseases.
Interested founders can apply through the NG Bio website, where they can find more information about the program and its requirements.
In recent months, NG Bio has been actively engaging with its portfolio companies, focusing on venture creation and support. The firm has updated its website to reflect its mission and portfolio, emphasizing its commitment to addressing harmful immune responses.
NG Bio continues to explore new investment opportunities in the life sciences sector, particularly in companies innovating in autoimmune disease therapeutics. Their proactive approach positions them as a key player in the UK biotech landscape.
What are NG Bio's investment criteria?
NG Bio focuses on early-stage investments in the life sciences sector, particularly in companies developing therapeutics for autoimmune diseases and inflammation. They look for innovative solutions that can significantly impact human health.
How can I pitch to NG Bio?
Founders can pitch their ideas through the NG Bio website. A well-structured pitch deck should include details about the technology, market opportunity, team, and financial projections. NG Bio values clarity and a strong vision for the future.
What makes NG Bio different from other investors?
NG Bio combines venture creation with investment, providing not only capital but also strategic support in financing, growth, and exit planning. Their focus on the life sciences sector and hands-on approach sets them apart.
What is NG Bio's geographic focus?
NG Bio primarily invests in companies based in the United Kingdom, although they may consider opportunities in other regions if they align with their investment thesis.
What is the typical check size for investments?
While specific check sizes are not disclosed, NG Bio invests at various stages, including pre-seed, seed, seed-plus, and Series A, indicating a flexible approach to funding based on the needs of the portfolio companies.
What kind of post-investment involvement does NG Bio have?
NG Bio actively engages with its portfolio companies, providing support in areas such as growth strategies, financing, and exit planning. Their team works closely with founders to help navigate the challenges of the biotech industry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.